Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Jan 02, 2025 11:30am
236 Views
Post# 36384464

RE:Exciting month ahead.

RE:Exciting month ahead.I'm commenting on the post from fastrack5.

regarding exciting month ahead.
I agree 100%.
I'm looking forward to the 13th if this month presentation. JP Morgan , all financial.
and
The " efficiency update" being presented at a conference the 25th of this month.
I could not help myself. Again some yr end dividends in my stock account. Put my $$ where my mouth is.
Save your rehetoric Bucky & Q30.:my new yrs resolution, put both of you on ignore.
also, check your inbox , I sent you a year end farewell.
Back to ONC ...this site BTW represents my guess less than 1% of shareholders.
many on here are very close, perhaps too close.
saying that.
taking the time to read, beyond this BB, I always recommend the company web site.
great presentation on there.
I bought into Onc as I strongly belive in the science. They have now advanced to the final phase, to get approval.
All science has trials that succeed & fail. Information is gathered from both.
They MUST have a business deal to proceed with MBc .
The panc trial is covered alongside CGAR & co- therapy with Roche, powerful team!
That BD will be announced alongside the MBc registration trial.
When & what, no idea.
We all want a buyout.
With the founder still off on extended sick leave, My instincts tell me a buyout is best for all.
all the best , in 2025 all.
Canadafan...

<< Previous
Bullboard Posts
Next >>